Novo's NVO denecimig biologics license application (BLA) review in the United States is facing an extended timeline after the FDA informed the company that the review of the investigational therapy for haemophilia A remains ongoing. The FDA has not provided a new date for regulatory action, with facility remediation activities cited as the reason for the extension. Novo said the agency has not identified any deficiencies related to the clinical efficacy or safety data included in the application. Novo's denecimig is an investigational FVIIIa-mimetic bispecific antibody being developed as a subcutaneous prophylactic treatment for adults and children with haemophilia A, including patients with inhibitors.
我们公开展示核心要点。创建免费账户后可继续阅读全文、保存、讨论，并结合市场和 OSINT 背景分析。